Are There Any Actions I Can Take If My Medication Is Impacted by a Shortage?

Why Drug Shortages Happen and Why They Affect Telehealth Patients Disproportionately

Drug shortages are not random. They arise from a narrow cluster of causes: manufacturing disruptions, raw-material bottlenecks, sudden demand spikes, and regulatory manufacturing holds. The FDA defines a drug shortage as "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug," a definition codified in the Federal Food, Drug, and Cosmetic Act Section 506C.

Telehealth patients who use brand-name GLP-1 receptor agonists, testosterone cypionate, progesterone, or peptide therapies are especially exposed. These medications are often sourced from a small number of manufacturers, and demand has grown sharply. Injectable semaglutide (Ozempic, Wegovy) appeared on the FDA shortage database in March 2022 and remained listed at various dose strengths through 2024 [1]. Tirzepatide (Mounjaro, Zepbound) followed a similar arc in 2023 [2].

The Supply Chain Problem in Plain Terms

Most active pharmaceutical ingredients for injectable medications are manufactured at a handful of facilities, many located outside the United States. A single FDA Form 483 inspection finding, a hurricane disrupting a Puerto Rico plant, or an unexpected 300 percent surge in prescriptions can remove a product from shelves within weeks. The American Society of Health-System Pharmacists (ASHP) tracked more than 300 active drug shortages in the United States as of late 2024 [3].

Why Telehealth Compounds the Problem

Telehealth prescriptions frequently route through mail-order specialty pharmacies that operate on tighter inventory buffers than large retail chains. When a shortage hits, mail-order queues freeze faster. Patients may receive no warning until a shipment simply does not arrive. Knowing this, building a short personal buffer stock during stable periods, when your prescriber and pharmacy permit it, is a reasonable strategy.

Step 1: Confirm the Shortage Is Official and Understand Its Scope

Before you take any action, verify that your medication is actually listed on the FDA's official Drug Shortages Database at accessdata.fda.gov/scripts/drugshortages [4]. The database is updated daily and tells you the specific manufacturer(s) affected, the shortage status (current, resolved, or discontinued), and any FDA communications about the cause.

What the Shortage Listing Actually Tells You

Each shortage entry includes the drug name, dosage form, strength, and the name of the manufacturer reporting the shortage. If only one manufacturer of a multi-source drug is affected, your pharmacy may be able to source from a different supplier without changing your prescription. Call your pharmacy first and ask: "Is there another manufacturer's version available?"

When to Escalate Immediately

If the drug has only one manufacturer or if all listed manufacturers are in shortage status, move to Step 2 without delay. Single-source shortages for brand-name biologics, such as semaglutide injection 2.4 mg (Wegovy), resolve more slowly because no generic equivalent exists and the manufacturing process for peptide-based injectables is complex.

Step 2: Contact Your Prescriber Within 48 Hours

Your prescriber is your most important resource during a shortage. They hold the authority to switch your prescription, authorize a therapeutic substitute, write for a different dose form, or contact the pharmacy directly on your behalf.

When you reach out, be specific. Tell them: the name and strength of the medication, the pharmacy you use, and what the pharmacy told you about expected restocking. Vague communications slow the process. A message that says "my Wegovy 1.7 mg pen is out of stock at CVS Specialty and the pharmacist says no restock date is available" gets a faster, more useful response than "I can't get my medication."

Therapeutic Substitution: What It Means for GLP-1 Patients

For patients using semaglutide (Ozempic or Wegovy) who cannot access their current dose, a prescriber might consider tirzepatide (Mounjaro or Zepbound) as an alternative GLP-1/GIP receptor agonist, depending on availability and your insurance coverage. These are not identical molecules. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide is a selective GLP-1 receptor agonist. The SURMOUNT-1 trial (N=2,539) found that tirzepatide 15 mg produced 20.9 percent mean body weight reduction at 72 weeks versus 3.1 percent with placebo [5]. That efficacy profile may make it a reasonable bridge for patients on semaglutide if their prescriber agrees.

Therapeutic Substitution for TRT and HRT

Testosterone cypionate shortages have occurred periodically. Your prescriber can substitute testosterone enanthate, which shares the same active hormone but uses a different ester and injection schedule (typically every 7 to 10 days versus every 7 to 14 days for cypionate). For HRT patients, if oral or patch estradiol is unavailable, a prescriber may authorize a compounded topical gel or a different patch formulation.

Requesting a 90-Day Supply

If your medication is currently available but you have received notice of an upcoming shortage, ask your prescriber to authorize a 90-day supply. Many insurers allow this for maintenance medications. Pair the request with documentation of the FDA shortage listing to accelerate insurer approval.

Step 3: Understand Your Compounding Pharmacy Options

The FDA allows 503A compounding pharmacies (traditional pharmacies that compound for individual patients) and 503B outsourcing facilities (larger facilities that compound for office stock) to produce copies of FDA-approved drugs that are on the official shortage list, provided they meet specific quality standards [6].

During the semaglutide shortage period, multiple 503A and 503B facilities produced compounded semaglutide. The FDA confirmed that this activity was permissible while semaglutide remained on the shortage list. Once the FDA removed semaglutide from the shortage list for specific dose strengths in late 2024, the regulatory picture shifted, and some compounders were required to wind down production. The status of any compounded product depends entirely on whether the reference drug remains on the current shortage list.

How to Verify a Compounding Pharmacy's Legitimacy

Not all compounding pharmacies meet the same safety standards. Before using any compounding pharmacy, verify:

1. The pharmacy holds a valid state pharmacy license. Check your state board of pharmacy website.
2. 503B outsourcing facilities are registered with the FDA. You can search the FDA's registered outsourcing facility list at fda.gov/drugs/human-drug-compounding/outsourcing-facility-registration [7].
3. The pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board) or verified by a recognized accrediting body.

What Compounded Does and Does Not Mean

Compounded semaglutide, for example, contains the same active ingredient as Wegovy or Ozempic but is not FDA-approved as a finished drug product. Quality, sterility, and concentration must be verified by the compounding facility. Ask the pharmacy for a certificate of analysis (COA) from a third-party laboratory for each batch. A reputable 503B facility will provide this routinely.

The HealthRX medical team uses the following internal triage framework when a patient reports a medication shortage. In the first 24 hours: confirm the FDA shortage listing and contact the dispensing pharmacy about alternative manufacturers. In hours 24 to 48: the prescribing clinician reviews therapeutic substitutes and initiates a prior authorization if needed. In days 3 to 7: if no branded alternative is available and the drug remains on the shortage list, evaluate a licensed compounding pharmacy option and order a COA before dispensing. Beyond day 7: if no solution is available, schedule a telehealth visit to reassess the treatment plan and consider a treatment pause with a documented return-to-therapy plan.

Step 4: Work With Your Insurance Company Proactively

Insurance companies have processes for handling drug shortages, but you must initiate contact. Do not wait for the insurer to reach out.

Prior Authorization for Alternatives

If your prescriber wants to switch you to a therapeutic substitute, your insurer may require a new prior authorization (PA). The PA process can take 3 to 15 business days under normal circumstances. Request that your prescriber file for urgent or expedited review, citing the active FDA shortage. Under the Consolidated Appropriations Act of 2021, many commercial insurers must respond to urgent PA requests within 72 hours [8].

Step Therapy Waivers

Some plans require you to try a lower-cost medication before approving your preferred drug (step therapy). If you were already stable on your original medication before the shortage, ask your prescriber to file a step therapy waiver based on clinical stability. Most states have enacted step therapy override laws. The National Alliance of Mental Illness (NAMI) tracks state step therapy laws, and as of 2024, 31 states had enacted protections requiring clinical exceptions [9].

Emergency Fill Provisions

Many insurers allow emergency fills of a 30-day supply without a prior authorization during a declared shortage. Ask your pharmacist to run the claim with an emergency fill override code. If the insurer denies it, your prescriber can call the insurer's pharmacist reviewer directly, which often resolves the issue within the same business day.

Step 5: Request an Early Refill

Most insurance plans allow refills when 75 to 80 percent of a supply has been used (roughly 22 to 24 days into a 30-day supply). During a declared shortage, many state boards of pharmacy and individual insurers extend early refill permissions to allow a refill as soon as the current supply drops below a 10-day supply.

Contact your pharmacy and say specifically: "I have been notified of a shortage of my medication. Can you run an early refill override based on the FDA shortage status?" If the pharmacist confirms the override is blocked by your insurer, your prescriber can call the insurer's clinical line and request a manual override. This works more often than patients expect.

Step 6: Use FDA and Government Resources Directly

Several federal resources exist specifically to help patients manage shortages, and most patients never use them.

FDA Drug Shortage Database

The FDA maintains a real-time database at accessdata.fda.gov/scripts/drugshortages [4]. You can search by drug name, active ingredient, or NDC number. The database shows current shortages, resolved shortages, and discontinued products. Checking this weekly when you are on a medication at risk of shortage gives you early warning to act before a shipment fails.

Reporting a Shortage to the FDA

Both patients and pharmacists can report shortages to the FDA through MedWatch at fda.gov/safety/medwatch [10]. Reports from patients are taken seriously. Aggregate shortage reports from patients have historically accelerated FDA engagement with manufacturers. Filing a report takes approximately 10 minutes.

ASHP Shortage Database

The American Society of Health-System Pharmacists maintains an independent shortage database at ashp.org/drug-shortages that pharmacists update and annotate with clinical notes about alternatives and timelines [3]. This database often contains more clinical detail than the FDA's listing, including notes about which manufacturers are in shortage versus which are not.

Step 7: Consider a Planned Treatment Pause With a Return-to-Therapy Protocol

If no substitution, compounding, or insurance solution resolves your access gap within 7 to 10 days, a short, planned treatment pause may be less harmful than unplanned dose skipping or self-adjusting doses.

What a Treatment Pause Looks Like for GLP-1 Patients

For patients on semaglutide or tirzepatide, a pause of 4 weeks or fewer typically produces modest weight regain rather than full rebound. The STEP-4 trial (N=803) found that patients who discontinued semaglutide 2.4 mg after 20 weeks of treatment regained two-thirds of their prior weight loss over the following 48 weeks [11]. A shorter pause of 4 weeks produced less dramatic regain in post-hoc analyses of STEP-4 data. Your prescriber should document the pause reason, expected duration, and a restart plan including the dose at which you will resume (typically stepping back one dose level).

Dietary and Lifestyle Bridges During a Pause

During a planned pause, focus on the behavioral components of your treatment plan: consistent protein intake of at least 1.2 g per kilogram of body weight per day, resistance training 2 to 3 times per week, and structured meal timing. These strategies will not replicate the appetite suppression of a GLP-1 agonist, but they reduce the rate of regain during a defined gap.

Pause Protocols for TRT Patients

A testosterone pause of 2 to 4 weeks rarely causes clinical hypogonadism in patients with natural testosterone production above 100 ng/dL at baseline, but patients who are severely hypogonadal (total testosterone <100 ng/dL pre-treatment) may experience symptomatic decline within 2 weeks. Your prescriber should check a baseline testosterone level before authorizing a pause and set a clinical threshold for early restart.

Step 8: Communicate Proactively With Your Telehealth Platform

If you are a telehealth patient, your platform's care team can often access pharmacy networks and shortage workarounds that individual patients cannot. Telehealth platforms that work with multiple dispensing pharmacies can reroute your prescription to a pharmacy with available inventory in a different region.

Contact your platform's support team and ask specifically: "Can my prescription be transferred to a pharmacy in a different state that currently has stock?" Interstate prescription transfers for Schedule III and lower controlled substances are permitted under federal law and most state laws. Testosterone cypionate is a Schedule III controlled substance and can be transferred to an out-of-state pharmacy with a new paper or electronic prescription from your prescriber.

For non-controlled medications like semaglutide or tirzepatide, your prescriber can send a new prescription to any licensed pharmacy in any state. There is no restriction on routing.

Practical Timeline: What to Do and When

The following sequence applies to most medication shortages for telehealth patients:

Day 1 (shortage noticed): Check the FDA shortage database. Call your pharmacy and ask about alternative manufacturers and expected restock timelines.

Day 1 to 2: Message your prescriber with specific drug name, strength, pharmacy name, and what the pharmacy told you. Request early refill if eligible.

Day 2 to 3: If no branded solution exists, ask your prescriber to evaluate therapeutic substitutes and initiate a prior authorization. Contact your insurer about emergency fill provisions.

Day 3 to 7: If therapeutic substitution is not viable, evaluate licensed compounding pharmacy options with your prescriber. Request COA documentation from any proposed compounder.

Day 7 to 10: If no access solution is confirmed, discuss a planned treatment pause with a documented restart protocol with your prescriber.

Ongoing: Report the shortage to FDA MedWatch. Check ASHP and FDA databases weekly until access is restored.